By Colin Kenny, GP, Dromore
In this study investigators examined 6401 people with diabetes who were being treated with pioglitazone and were registered on a Taiwanese health database. They compared them with 12,802 people with type 2 diabetes who were age- and sex-matched and who had never been treated with pioglitazone. Both cohorts were free from dementia at baseline.
In total, 113 (1.8%) and 323 (2.5%) patients in the pioglitazone-treated and comparison cohorts, respectively, developed dementia during the 5-year follow-up. The reduction in risk of dementia, after adjustment for age, sex, hypertension and stroke, was found to be 23% in the pioglitazone-treated cohort (compared with that in the comparison cohort). The investigators concluded that pioglitazone has a time- and dose-dependent protective association with dementia in people with diabetes.
To access the full publication, click here (log-in or purchase required)
